Zemplar

Paricalcitol (Zemplar) is an intravenous vitamin D analog prescribed to manage secondary hyperparathyroidism in chronic kidney disease. It helps regulate calcium and phosphorus levels. This EU-manufactured treatment supports bone health in dialysis patients.

Paricalcitol is used to treat secondary hyperparathyroidism in adults and pediatric patients 5 years and older with chronic kidney disease. It works by reducing elevated parathyroid hormone levels that can lead to bone disorders. Patients undergoing dialysis often require this medication to maintain mineral balance. The intravenous form is administered by healthcare professionals during treatment sessions.

Paricalcitol helps normalize calcium and phosphorus levels in the bloodstream, which may improve symptoms related to bone discomfort or weakness. Some patients report reduced itching or muscle cramps as their mineral levels stabilize. Regular monitoring is typically required to assess response and adjust dosing as needed.

Paricalcitol should only be used under medical supervision due to the risk of elevated calcium levels. Patients with a history of seizures or heart conditions should inform their healthcare provider before starting treatment. Blood tests are commonly performed to check calcium, phosphorus, and parathyroid hormone levels during therapy.

Certain medications, including strong CYP3A inhibitors like ketoconazole, may increase paricalcitol levels in the blood. Patients should discuss all prescription drugs, over-the-counter supplements, and herbal products with their doctor. Grapefruit products may also interact with paricalcitol and should be avoided unless approved by a healthcare professional.